The cell cycle pathway is the ordered sequence of events a cell goes through to grow and divide into two daughter cells, and it is regulated primarily by a family of enzymes called cyclin-dependent kinases working in concert with multiple checkpoint systems that monitor whether conditions are safe to proceed. In essence, cyclin-dependent kinases act as the engine, while checkpoints act as the brakes. The interplay between the two determines whether a cell divides, pauses to fix a problem, or exits the cycle altogether, and the disruption of this interplay is one of the defining features of cancer.
The Four Phases of Division
A dividing cell passes through four main stages. During G1 (the first gap phase), the cell grows in size, produces proteins, and assesses whether external signals and internal conditions favor division. S phase (synthesis) is when the cell copies its entire genome so that each daughter cell will receive a complete set of chromosomes. G2 (the second gap phase) is a second growth interval during which the cell checks for replication errors and prepares the molecular machinery for physical division. Finally, M phase (mitosis) is the dramatic climax: the duplicated chromosomes line up, separate, and the cell pinches in half.
These phases are not simply on a timer. The transitions between them are gated by molecular switches that will not flip until specific conditions are met. A cell that encounters DNA damage in G2, for instance, can stall before entering mitosis. A cell that lacks growth factor stimulation in G1 will not commit to copying its DNA. This conditional logic is what makes the cell cycle a regulated pathway rather than a passive countdown.
Cyclin-Dependent Kinases and Their Partners
The enzymes that drive a cell from one phase to the next are cyclin-dependent kinases, or CDKs. On their own, CDKs are inactive. They need to bind to a partner protein called a cyclin to switch on, and different cyclins accumulate at different stages of the cycle, so the right CDK is activated at the right time. Cyclin D pairs with CDK4 or CDK6 in early G1. Cyclin E pairs with CDK2 to trigger the start of S phase. Cyclin A partners with CDK2 during DNA replication and later with CDK1 as the cell moves toward mitosis. Cyclin B and CDK1 together drive mitotic entry.
Even after a cyclin binds its CDK partner, the complex still needs a final activation step. A separate kinase complex centered on CDK7 phosphorylates the cyclin-CDK pair at a specific spot in its activation loop, fully turning on its enzymatic activity. CDK1, CDK2, CDK4, and CDK6 are all activated this way, each at a slightly different residue.1Signal Transduction and Targeted Therapy. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease The system also has multiple ways to shut CDKs off. Two kinases called WEE1 and MYT1 can phosphorylate CDKs at inhibitory sites, and a family of small inhibitor proteins can physically block CDK activity by wedging into the catalytic cleft.1Signal Transduction and Targeted Therapy. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Work in fission yeast has shown that the substrate preferences of different CDK complexes overlap more than researchers once assumed. S-phase CDKs and mitotic CDKs recognize a remarkably similar set of target proteins. Under normal conditions, S-phase CDKs cannot trigger mitosis, but removing a counteracting phosphatase from the centrosome allows them to do so, suggesting that the difference between “time to replicate” and “time to divide” comes down to quantitative thresholds of CDK activity rather than rigid specialization of each complex.2Nature. Core control principles of the eukaryotic cell cycle
Growth Signals and the Decision to Divide
Before a cell commits to division, it needs permission from its environment. Growth factors bind to receptors on the cell surface and trigger intracellular signaling cascades. One of the best studied of these runs through a protein called Ras. When growth factor receptors activate Ras, it kicks off a chain of signals that accomplish two things critical for cell cycle entry: it drives up levels of cyclin D1, and it drives down levels of an inhibitor protein called p27, which otherwise keeps CDK2 complexes in check.3PubMed Central. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1 If you force cyclin D1 to stay on regardless of Ras, cells can proliferate without normal growth factor signaling, which is one reason cyclin D1 overexpression shows up so often in cancer.
The Ras/Raf/MEK/ERK signaling cascade is not just theoretical plumbing. Overactivation of growth factor receptors, like the insulin-like growth factor 1 receptor, has been shown to pump up cyclin D1 through exactly this pathway, accelerating the transition from G1 into S phase and fueling tumor growth in cancers such as breast cancer.4PubMed Central. IGF-1R promotes the expression of cyclin D1 protein and accelerates the G1/S transition by activating Ras/Raf/MEK/ERK signaling pathway
The Restriction Point
Somewhere in late G1, a cell crosses a point of no return called the restriction point. Before this threshold, removing growth factors will cause the cell to stall. After it, the cell will proceed into S phase even if growth factors vanish. The molecular basis of this commitment involves a switch built from two proteins: Rb (the retinoblastoma protein) and E2F (a transcription factor that activates genes needed for DNA replication). In its default state, Rb binds and silences E2F. As cyclin D-CDK4/6 and then cyclin E-CDK2 progressively phosphorylate Rb, E2F is released and flips on its own gene targets, creating a self-reinforcing loop.
Single-cell measurements have confirmed that the Rb-E2F circuit functions as a true bistable switch, converting graded growth factor levels into an all-or-none E2F response. Once E2F switches on, it stays on even if growth factors are removed, and this molecular memory corresponds directly to a cell’s ability to cross the restriction point.5Nature Cell Biology. A bistable Rb-E2F switch underlies the restriction point This is why the decision to divide is not smoothly reversible: it is a digital flip, not an analog dial.
Safeguarding DNA Replication
Copying the genome once per cycle is essential; copying it twice would be catastrophic. The cell prevents re-replication through a licensing system. In late mitosis and early G1, when CDK activity is low, origins of replication along the chromosomes are “licensed” by loading a set of proteins onto them. When CDK activity rises to an intermediate level at the start of S phase, those licensed origins fire and begin replication. Crucially, the same intermediate CDK activity that triggers firing also prevents new origins from being licensed, so origins that have already fired cannot reload their start machinery. A still-higher level of CDK activity later pushes the cell into mitosis.6PubMed Central. Preventing DNA over-replication: a Cdk perspective The elegance here is that a single variable, the overall level of CDK activity, creates three distinct states: license, fire, and divide.
DNA Damage Checkpoints
If DNA is broken or incompletely replicated, a cell that blunders ahead risks passing mutations to its daughters or attempting to pull apart tangled chromosomes. To prevent this, cells have evolved DNA damage checkpoints that detect problems and halt the cycle until repairs are complete. Two sensor kinases, ATM and ATR, are at the top of the response. ATM responds primarily to double-strand breaks, while ATR monitors stalled replication forks. Each activates a downstream kinase (Chk2 and Chk1, respectively) that converges on the cell cycle machinery to arrest progression and give repair enzymes time to work.7PubMed Central. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
A key downstream target of this checkpoint is the tumor suppressor p53, often called “the guardian of the genome.” Stabilized by checkpoint signaling, p53 turns on genes that stall the cycle in G1 (primarily through the CDK inhibitor p21) or, if damage is severe, push the cell into programmed death. Experiments in sea urchin embryos have illustrated this dose-dependent logic neatly: low concentrations of DNA-damaging agents caused a temporary cell cycle delay followed by successful repair and recovery, while high concentrations triggered hallmarks of apoptosis.8Cellular and Molecular Life Sciences. Sea urchin embryo as a model for analysis of the signaling pathways linking DNA damage checkpoint, DNA repair and apoptosis The checkpoint system, in other words, is not just an on/off gate. It gauges the severity of the problem and chooses the appropriate response.
The Spindle Assembly Checkpoint and Anaphase
During mitosis, duplicated chromosomes must attach to opposite poles of the spindle apparatus so that each daughter cell gets exactly one copy. The spindle assembly checkpoint holds the cell at metaphase until every chromosome pair has achieved proper bipolar attachment. Unattached or improperly attached chromosomes generate a “wait” signal built from a checkpoint complex containing a protein called BubR1. This complex inhibits Cdc20, a co-activator needed to switch on a large protein-destruction machine called the anaphase-promoting complex (APC/C).9Developmental Cell. Purified Human BubR1 Kinase Protects the Anaphase-Promoting Complex from Cdc20 Inhibition
Once every chromosome is properly connected, the checkpoint signal dissipates and the APC/C roars to life. It tags a protein called securin for destruction. Securin normally handcuffs an enzyme called separase. When securin is degraded, separase is freed to cut the molecular glue holding sister chromosomes together, and anaphase begins.10PubMed. Dual inhibition of sister chromatid separation at metaphase The APC/C also destroys mitotic cyclins, which drops CDK activity sharply and allows the cell to exit mitosis. The order of these destruction events matters: anaphase starts when less than half of securin has been degraded, well before the cyclins are fully cleared.11PubMed Central. Multiple mechanisms determine the order of APC/C substrate degradation in mitosis
Leaving the Cycle
Not every cell keeps dividing forever. Most cells in an adult body are not actively cycling. They sit in a resting state called G0, or quiescence, where they are alive and metabolically active but not preparing to divide. Quiescent cells retain the ability to re-enter the cell cycle if the right signals arrive.12PubMed Central. Quiescence Entry, Maintenance, and Exit in Adult Stem Cells Adult stem cells, for instance, spend much of their time in quiescence, waking up only when tissue repair demands fresh cells. Maintaining quiescence requires active cellular programs; it is not simply the absence of division signals, and phosphatases play an important role in keeping the quiescent state stable.13PubMed Central. G0 or no-G0: phosphatase control of quiescence and cell cycle entry
Senescence is a different kind of exit. Senescent cells leave the cell cycle permanently. Recent work has clarified what makes senescence irreversible when the p53-p21 and p16-Rb pathways involved also mediate reversible quiescence. The key appears to be constitutive degradation of the protein MYC, a major driver of proliferation. In senescent cells, MYC is continuously destroyed, and expressing a non-degradable version of MYC causes senescent cells to start dividing again. Conversely, knocking down MYC in quiescent cells converts them to senescence.14PubMed. Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation Senescence serves as a safety net against uncontrolled proliferation, but it comes at a cost: senescent cells accumulate with age and secrete inflammatory signals that contribute to tissue dysfunction.
When Regulation Fails
Cancer, at its core, is a disease of cell cycle deregulation. Mutations that remove checkpoints or lock growth-promoting signals in the “on” position allow cells to divide without permission and without quality control. Two pathways are hit with particular frequency. The Rb pathway, which controls the restriction point, is disrupted in a wide range of tumors through loss of Rb itself, loss of the CDK inhibitor p16, or overexpression of cyclin D1 or CDK4. These mutations tend to be mutually exclusive within a given tumor: one hit to the pathway is enough to disable it, so there is no selective pressure for a second.15Cancer Cell. The RB and p53 Pathways in Cancer
The p53 pathway is the other frequent casualty. The p53 gene is mutated in more than half of all human cancers, and in many of the tumors that retain a normal p53 gene, other genes that feed into p53 signaling are altered instead.15Cancer Cell. The RB and p53 Pathways in Cancer Together, Rb pathway disruption removes the restriction point gate, and p53 pathway disruption disables the DNA damage checkpoint. A cell with both defects can divide with damaged DNA and ignore signals to stop, which is a recipe for accumulating further mutations and becoming increasingly aggressive.
Drugs That Target the Cell Cycle Machinery
Understanding how CDKs drive the cycle has opened the door to drugs that jam specific gears. The most successful so far are small-molecule inhibitors of CDK4 and CDK6, which keep Rb in its growth-suppressing state and prevent cells from passing through G1. Three of these drugs (palbociclib, ribociclib, and abemaciclib) have become standard treatment for hormone receptor-positive breast cancer, where they are combined with hormonal therapy. Clinical trials are testing them in lung, colorectal, and other cancers as well.16PubMed Central. CDK4 and CDK6 kinases: From basic science to cancer therapy
CDK4/6 inhibitors work best when the Rb protein is still intact, because the drugs depend on Rb to suppress E2F-driven gene expression. Tumors that have already lost Rb are resistant. This is a recurring theme in cell cycle-targeted therapy: the drug exploits a particular checkpoint, so it only works in tumors that still have that checkpoint’s hardware in place. Knowing the mutational profile of a tumor is therefore critical to choosing the right treatment.
Nutrient Sensing and the Cell Cycle
Growth factors are not the only environmental input the cell cycle integrates. Nutrient and energy status feed into the decision to grow and divide through a separate signaling axis. A central node is mTOR (mechanistic target of rapamycin), a kinase that promotes cell growth and protein synthesis when amino acids and energy are plentiful. When energy drops and intracellular ATP falls, an energy sensor called AMPK switches on and shuts down mTOR signaling, suppressing cell growth.17PubMed Central. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth The AMPK-mTOR connection is conserved across essentially all eukaryotes, from yeast to humans, suggesting it is an ancient and fundamental growth-control module.
Recent evidence shows that mTOR activity does not remain flat throughout the cell cycle but oscillates, peaking at times when the cell needs bursts of biosynthesis.18Cell Reports. mTORC1 activity oscillates throughout the cell cycle and is required for cell proliferation This makes intuitive sense: building a new cell requires massive production of membranes, ribosomes, and organelles, and pausing growth when nutrients are scarce prevents the cell from overcommitting to a division it cannot complete. Drugs that inhibit mTOR, such as rapamycin and its derivatives, are used in transplant medicine and certain cancers precisely because they exploit this link between metabolism and proliferation.
Variations on the Standard Cycle
The textbook four-phase cycle describes most dividing cells in an adult body, but some cell types run modified versions. Early embryonic cells, for instance, blast through divisions at extraordinary speed, sometimes completing an entire cycle in under 30 minutes. They largely skip G1 and G2, alternating between S phase and mitosis in rapid succession. Coordinating these cleavage divisions across a large embryo requires chemical waves and cytoplasmic flows rather than conventional growth checkpoints.19PubMed Central. Cell cycle control during early embryogenesis Only later, when the embryo’s own genome activates and maternal supplies run low, do gap phases and checkpoints kick in.
Meiosis is another major departure. Used exclusively to produce eggs and sperm, the meiotic cell cycle involves one round of DNA replication followed by two rounds of chromosome separation, yielding cells with half the normal chromosome number. Rather than inventing entirely new machinery, cells repurpose the standard mitotic regulators but swap in meiosis-specific versions of key proteins or layer on meiosis-specific modifiers that change how the core CDK-cyclin complexes behave.20PubMed. Meiosis: how to create a specialized cell cycle The result is that much of the logic, CDK activity rising and falling, checkpoints gating transitions, destruction machines clearing the way, is recognizably the same. The differences lie in which specific proteins are plugged into each role and how the transitions between the two divisions are handled.
Endoreplication is yet another variant, found in cells that copy their DNA without dividing at all. Liver cells and certain plant cells, for example, go through repeated S phases to amplify their genome, growing very large in the process. They achieve this by suppressing mitotic CDK activity while allowing S-phase CDK activity to cycle, effectively running the replication program on a loop without ever entering M phase. These variations reinforce the broader point that the cell cycle is a modular system: its core components can be reconfigured for vastly different biological purposes without being built from scratch.